ITUS (NYSE:ANIX) Research Coverage Started at Aegis

Aegis initiated coverage on shares of ITUS (NYSE:ANIX) in a report released on Monday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $8.50 target price on the stock.

Several other equities analysts also recently issued reports on ANIX. Zacks Investment Research upgraded shares of ITUS from a hold rating to a buy rating and set a $3.50 price objective on the stock in a report on Wednesday, January 1st. B. Riley cut their price objective on shares of ITUS from $11.25 to $8.00 and set a buy rating on the stock in a report on Monday, December 30th.

Shares of ANIX traded up $0.03 during mid-day trading on Monday, hitting $1.63. 64,500 shares of the company traded hands, compared to its average volume of 71,785. ITUS has a 1-year low of $1.50 and a 1-year high of $5.45. The business has a 50 day moving average of $2.79 and a 200 day moving average of $3.45.

ITUS (NYSE:ANIX) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13).

In other ITUS news, Director Arnold M. Baskies purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, January 17th. The shares were bought at an average price of $3.74 per share, for a total transaction of $37,400.00. Following the acquisition, the director now owns 21,000 shares in the company, valued at $78,540. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amit Kumar purchased 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 14th. The stock was acquired at an average price of $2.99 per share, for a total transaction of $59,800.00. Following the acquisition, the chief executive officer now owns 194,000 shares in the company, valued at approximately $580,060. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 43,199 shares of company stock worth $133,914.

About ITUS

Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.

Recommended Story: What is the LIBOR?

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.